Stock-outs of antiretroviral and tuberculosis medicines in South Africa: A national cross-sectional survey
Open Access
- 12 March 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (3) , e0212405
Abstract
HIV and TB programs have rapidly scaled-up over the past decade in Sub-Saharan Africa and uninterrupted supplies of those medicines are critical to their success. However, estimates of stock-outs are largely unknown. This survey aimed to estimate the extent of stock-outs of antiretroviral and TB medicines in public health facilities across South Africa, which has the world’s largest antiretroviral treatment (ART) program and a rising multidrug-resistant TB epidemic. We conducted a cross-sectional telephonic survey (October—December 2015) of public health facilities. Facilities were asked about the prevalence of stock-outs on the day of the survey and in the preceding three months, their duration and impact. Nationwide, of 3547 eligible health facilities, 79% (2804) could be reached telephonically. 88% (2463) participated and 4% (93) were excluded as they did not provide ART or TB treatment. Of the 2370 included facilities, 20% (485) reported a stock-out of at least 1 ARV and/or TB-related medicine on the day of contact and 36% (864) during the three months prior to contact, ranging from 74% (163/220) of health facilities in Mpumalanga to 12% (32/261) in the Western Cape province. These 864 facilities reported 1475 individual stock-outs, with one to fourteen different medicines out of stock per facility. Information on impact was provided in 98% (1449/1475) of stock-outs: 25% (366) resulted in a high impact outcome, where patients left the facility without medicine or were provided with an incomplete regimen. Of the 757 stock-outs that were resolved 70% (527) lasted longer than one month. There was a high prevalence of stock-outs nationwide. Large interprovincial differences in stock-out occurrence, duration, and impact suggest differences in provincial ability to prevent, mitigate and cope within the same framework. End-user monitoring of the supply chain by patients and civil society has the potential to increase transparency and complement public sector monitoring systems.Keywords
This publication has 21 references indexed in Scilit:
- Reframing HIV care: putting people at the centre of antiretroviral deliveryTropical Medicine & International Health, 2015
- Effects of Treatment Interruption Patterns on Treatment Success Among Patients With Multidrug-Resistant Tuberculosis in Armenia and AbkhaziaThe Journal of Infectious Diseases, 2014
- Stock-outs of antiretroviral drugs and coping strategies used to prevent changes in treatment regimens in Kinondoni District, Tanzania: a cross-sectional studyJournal of Pharmaceutical Policy and Practice, 2014
- Antiretroviral drug supply challenges in the era of scaling up ART in MalawiJournal of the International AIDS Society, 2011
- Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and deathAIDS, 2011
- Impact of Drug Stock-Outs on Death and Retention to Care among HIV-Infected Patients on Combination Antiretroviral Therapy in Abidjan, Côte d'IvoirePLOS ONE, 2010
- Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these?Globalization and Health, 2010
- Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or deathHIV Medicine, 2007
- Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi2007
- Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006